Suppr超能文献

药物洗脱支架时代经皮冠状动脉介入治疗与手术治疗多支血管病变的成本效果系统评价。

A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era.

机构信息

Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology and Preventive Medicine (DEPM), Monash University, 6th Floor, 99 Commercial Rd, Melbourne, VIC 3004, Australia.

Cardiothoracic Unit, Geelong Hospital, Geelong, VIC, Australia.

出版信息

Eur Heart J Qual Care Clin Outcomes. 2016 Oct 1;2(4):261-270. doi: 10.1093/ehjqcco/qcw007.

Abstract

AIMS

The suitability of percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), for patients with complex multivessel coronary artery disease (MVCAD) remains a contentious topic. While the body of evidence regarding the clinical effectiveness of these revascularization strategies is growing, there is limited evidence concerning their long-term cost-effectiveness. We aim to critically appraise the body of literature investigating the cost-effectiveness of CABG compared with PCI using stents, and to assess the quality of the economic evidence available.

METHODS AND RESULTS

A systematic review was performed across six electronic databases; Medline, Embase, the NHS Economic Evaluation Database, the Database of Abstracts of Reviews of Effects, the health technology assessment database, and the Cochrane Library. All studies comparing economic attractiveness of CABG vs. PCI using bare-metal stents (BMS) or drug-eluting stents (DES) in balanced groups of patients were considered. Sixteen studies were included. These comprised studies of conventional CABG vs. BMS (n = 8), or DES (n = 4); off-pump CABG vs. BMS (n = 2), or DES (n = 1); and minimally invasive direct CABG vs. BMS (n = 2). The majority adopted a healthcare payer perspective (n = 14). The incremental cost-effectiveness ratios (ICERs) reported across studies varied widely according to perspective and time horizon. Favourable lifetime ICERs were reported for CABG in three trials. For patients with left main coronary artery disease, however, DES was reported as the dominant (more effective and cost-saving) strategy in one study.

CONCLUSION

Overall, CABG rather than PCI was the favoured cost-effective treatment for complex MVCAD in the long term. While the evidence base for the cost-effectiveness of DES compared with CABG is growing, there is a need for more evaluations adopting a societal perspective, and time horizons of a lifetime or 10 or more years.

摘要

目的

经皮冠状动脉介入治疗(PCI)与冠状动脉旁路移植术(CABG)相比,用于治疗复杂多血管冠状动脉疾病(MVCAD)的适宜性仍然是一个有争议的话题。尽管关于这些血运重建策略临床效果的证据越来越多,但关于其长期成本效益的证据有限。我们旨在批判性地评估比较 CABG 与 PCI 加支架的文献,评估现有经济证据的质量。

方法和结果

我们在六个电子数据库中进行了系统评价;Medline、Embase、NHS 经济评估数据库、疗效评价文摘数据库、卫生技术评估数据库和 Cochrane 图书馆。所有比较平衡组患者 CABG 与 PCI(使用裸金属支架(BMS)或药物洗脱支架(DES))的经济性的研究均被考虑。纳入了 16 项研究。这些研究包括传统 CABG 与 BMS(n = 8)或 DES(n = 4)的比较;非体外循环 CABG 与 BMS(n = 2)或 DES(n = 1)的比较;以及微创直接 CABG 与 BMS(n = 2)的比较。大多数研究采用医疗保健支付者视角(n = 14)。研究报告的增量成本效果比(ICERs)因视角和时间范围而异。有三项试验报告了 CABG 的有利终生 ICERs。然而,对于左主干冠状动脉疾病患者,一项研究报告 DES 是更有效的(更有效且节省成本)策略。

结论

总体而言,长期来看,CABG 而不是 PCI 是治疗复杂 MVCAD 的更有效和更具成本效益的治疗方法。尽管关于 DES 与 CABG 的成本效益的证据基础正在不断增加,但需要更多采用社会视角的评估,并采用终生或 10 年或更长时间的时间范围。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验